John Sweetenham

10.9k total citations · 2 hit papers
143 papers, 4.6k citations indexed

About

John Sweetenham is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, John Sweetenham has authored 143 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pathology and Forensic Medicine, 68 papers in Oncology and 43 papers in Genetics. Recurrent topics in John Sweetenham's work include Lymphoma Diagnosis and Treatment (87 papers), Chronic Lymphocytic Leukemia Research (35 papers) and Viral-associated cancers and disorders (30 papers). John Sweetenham is often cited by papers focused on Lymphoma Diagnosis and Treatment (87 papers), Chronic Lymphocytic Leukemia Research (35 papers) and Viral-associated cancers and disorders (30 papers). John Sweetenham collaborates with scholars based in United States, United Kingdom and Italy. John Sweetenham's co-authors include Graham M. Mead, Lisa Rybicki, Brad Pohlman, Ronald Sobecks, Julie M. Vose, Robert M. Dean, Brian J. Bolwell, Dennis H. Wright, Anthony H. Goldstone and John P. Leonard and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

John Sweetenham

140 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

2009 590 citations John Sweetenham et al. profile →
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 477 citations Craig H. Moskowitz, Auayporn Nademanee et al. The Lancet profile →

Peers

Countries citing papers authored by John Sweetenham

Since Specialization

Citations

This map shows the geographic impact of John Sweetenham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Sweetenham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Sweetenham more than expected).

Fields of papers citing papers by John Sweetenham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Sweetenham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Sweetenham. The network helps show where John Sweetenham may publish in the future.

Co-authorship network of co-authors of John Sweetenham

This figure shows the co-authorship network connecting the top 25 collaborators of John Sweetenham. A scholar is included among the top collaborators of John Sweetenham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Sweetenham. John Sweetenham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enhancing Readability of Online Patient-Facing Content: The Role of AI Chatbots in Improving Cancer Information Accessibility 2024 ·Journal of the National Comprehensive Cancer Network ·(unknown), Gilbert Z. Murimwa, (unknown), J. Stewart, (unknown), Jonathan Rodrı́guez, John Sweetenham, Herbert J. Zeh, Sam C. Wang, Patricio M. Polanco	24
2	Shattering myths regarding Hispanic ethnicity and survival in acute myeloid leukemia: Insights from the National Cancer Database. 2023 ·Journal of Clinical Oncology ·(unknown), Adeel Khan, (unknown), Urvashi Pandey, Fieke W. Hoff, Stephen S. Chung, Praveen Ramakrishnan Geethakumari, Robert H. Collins, Elizabeth Paulk, John Sweetenham, Yazan F. Madanat	0
3	NCCN Policy Summit: Cancer Care in the Workplace: Building a 21st Century Workplace for Patients, Survivors, and Caretakers 2023 ·Journal of the National Comprehensive Cancer Network ·Victoria Hood, (unknown), (unknown), (unknown), John Sweetenham, (unknown), (unknown), (unknown), Randy Jones, (unknown), Robert W. Carlson	1
4	Clinical Controversies of Double-Hit Lymphoma 2015 ·Deborah M. Stephens, John Sweetenham	4
5	Early FDG-PET adapted treatment improves the outcome of early FDG-PET-positive patients with stages I/II Hodgkin lymphoma (HL): final results of the randomized intergroup EORTC/LYSA/FIL H10 trial. 2015 ·John Sweetenham	8
6	Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → 2015 ·The Lancet ·Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Eric L. Sievers, Andy Chi, Emily K. Larsen, Naomi Hunder, Jan Walewski	477
7	Ocular Adnexal Lymphoma: Assessment of a Tumor-Node-Metastasis Staging System 2013 ·Ophthalmology ·Mary E. Aronow, Craig A. Portell, Lisa Rybicki, John Sweetenham, Arun D. Singh	27
8	The non‐relapse mortality rate for patients with diffuse large B‐cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls 2011 ·British Journal of Haematology ·Brian T. Hill, Lisa Rybicki, Brian J. Bolwell, Stephen D. Smith, Robert M. Dean, Matt Kalaycio, Brad Pohlman, Shawnda Tench, Ronald Sobecks, Steven Andrèsen, Edward A. Copelan, John Sweetenham	37
9	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 2009 ·Journal of Clinical Oncology ·Peter Hoskin, Lisa Lowry, Alan Horwich, Andrew Jack, (unknown), Barry W. Hancock, Paul Smith, Wendi Qian, (unknown), Bilyana Popova, Andrew R. Pettitt, David Cunningham, Ruth Pettengell, John Sweetenham, David C. Linch, Peter Johnson	124
10	High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison withde novodiffuse large B-cell lymphoma 2009 ·Leukemia & lymphoma ·Stephen D. Smith, Brian J. Bolwell, Anjali S. Advani, Steven Andrèsen, (unknown), Robert M. Dean, Eric D. Hsi, Matt Kalaycio, Brad Pohlman, Lisa Rybicki, John Sweetenham	10
11	Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma 2008 ·Biology of Blood and Marrow Transplantation ·Anuj Mahindra, Brian J. Bolwell, Ronald Sobecks, Lisa Rybicki, Brad Pohlman, Robert M. Dean, Steve Andresen, John Sweetenham, Matt Kalaycio, Edward A. Copelan	36
12	A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma 2008 ·Bone Marrow Transplantation ·Edward A. Copelan, Brad Pohlman, Lisa Rybicki, M Kalaycio, Ronald Sobecks, S Andresen, Robert M. Dean, Anna P. Koo, Jonathan Chan, John Sweetenham, Brian J. Bolwell	11
13	Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation 2008 ·Bone Marrow Transplantation ·Ronald Sobecks, Edward J. Ball, Medhat Askar, Karl S. Theil, Lisa Rybicki, Dawn Thomas, Stacey Brown, M Kalaycio, Steve Andresen, Brad Pohlman, Robert M. Dean, John Sweetenham, Roger M. Macklis, (unknown), (unknown), Edward A. Copelan, J. Maciejewski, Brian J. Bolwell	13
14	Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease 2005 ·Hematology ·John Sweetenham	28
15	A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma 2002 ·Annals of Hematology ·(unknown), John Sweetenham, Ruth Pickering, Lynsey Brown, Bridget S. Wilkins	36
16	Automated Immature Reticulocyte Counts Are Early Markers of Engraftment Following Autologous PBSC Transplantation in Patients with Lymphoma 2000 ·Journal of Hematotherapy & Stem Cell Research ·(unknown), (unknown), (unknown), John Sweetenham, Andrew Duncombe	13
17	Immunotherapy of mantle cell lymphoma (MCL), lymphoplasmacytoid lymphoma (LPC) and Waldenstrom's macroglobulinemia (WM), and small lymphocytic lymphoma (SLL) with rituximab (IDEC-C288): Preliminary results of an ongoing international multicentre trial 1998 ·British Journal of Haematology ·(unknown), (unknown), David Cunningham, Răzvan Popescu, (unknown), F. Cavalli, B Coiffier, Peter Johnson, Christian Gisselbrecht, Corinne Haïoun, E.M. Bessell, John Sweetenham, John Radford, Aziz Benzohra, TA Lister	3
18	Endothelial cell precursors are normal components of human umbilical cord blood 1997 ·British Journal of Haematology ·Mie Nieda, Andrew J. Nicol, P. A. Denning‐Kendall, John Sweetenham, B. A. Bradley, Jill Hows	116
19	Adult lymphoblastic lymphoma: High incidence of central nervous system relapse in patients treated with the Stanford University protocol 1992 ·Annals of Oncology ·John Sweetenham, Graham M. Mead, J. M. A. Whitehouse	12
20	Clinical features and management of malignant histiocytosis of the intestine 1987 ·Cancer ·Graham M. Mead, J. M. A. Whitehouse, J. F. Thompson, John Sweetenham, Christopher J. Williams, Dennis H. Wright	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact